Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Andrea Corona Altimmunes GLP-1 drug shows positive results for alcohol use disorder On Tuesday, Altimmune announced topline data from their Phase 2 RECLAIM trial showing that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced the number of heavy drinking days compared to placebo in patients with moderate to severe alcohol use disorder
Timing can make a difference
Slow increases in training can protect healing quality
That's why I want to help people feel better first
![Physiologic effects of GLP-1 (adapted from Granata et al. [11])](https://www.researchgate.net/publication/359199250/figure/fig1/AS:11431281081130351@1661532031197/Physiologic-effects-of-GLP-1-adapted-from-Granata-et-al-11.png)
US$ 28.69
US$ 25.35
US$ 29.62
